ampk glp-1 Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged activation AMPK-Mediated Multi-Organ Protective Effects of

Background Postprandial hypoglycemia (PH) is a significant complication following upper gastrointestinal (GI) surgery, characterized by postprandial glucose fluctuations and diverse clinical manifestations

GLP-1 users can donate eggs

Objective To assess whether use of glucagon-like peptide-1 (GLP-1) receptor agonists before upper gastrointestinal endoscopy is associated with increased risk of pulmonary aspiration or discontinuation of the procedure compared with sodium-glucose cotransporter-2 (SGLT-2) inhibitors

Losing too much of it may compromise metabolic flexibility and longevity

Limitations The major limitations of the studies that are included in this systematic review are the enrollment of healthy subjects and insufficient data in conditions that might affect pharmacokinetics (e.g., kidney dysfunction)

For users this could segway into an expansion of the private market and for payers this could provide an affordable entry point for public reimbursement